Choices for Increased Mobility Act of 2025
Summary
The Choices for Increased Mobility Act of 2025, reported out of committee 45-0, requires CMS to create separate billing codes for ultralightweight manual wheelchairs with titanium/carbon fiber bases, allowing suppliers to charge beneficiaries the price difference. This is a narrow regulatory change with no direct funding, minimal near-term market impact, and limited to the DME supply chain.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Bill requires CMS to create separate billing codes for ultralightweight manual wheelchairs with titanium/carbon fiber bases, allowing suppliers to charge beneficiaries the difference.
- 2.No direct government funding authorized; impact is limited to DME reimbursement structure and beneficiary out-of-pocket costs.
- 3.Minimal near-term market impact; no major public company is directly and significantly affected.
Market Implications
The bill's impact on public equities is negligible. DME suppliers are largely private or small-cap, and the premium wheelchair market is a small niche. PRVA's exposure is indirect and minimal. ENS's link is speculative. Investors should not adjust positions based on this bill.
Full Analysis
The Choices for Increased Mobility Act of 2025 (HR1703) was ordered to be reported by the House committee on May 21, 2026, with a unanimous 45-0 vote. The bill amends Medicare Part B payment rules for ultralightweight manual wheelchairs by requiring CMS to establish at least two HCPCS codes for wheelchair bases—one for titanium/carbon fiber construction and one for standard materials. Suppliers receive standard Medicare payment but can bill beneficiaries for the difference between that payment and their actual charge. The bill does not authorize any new funding; it is a regulatory change affecting reimbursement coding and beneficiary liability.
The money trail is indirect: no direct government spending is authorized. Instead, the bill creates a mechanism for suppliers to capture additional revenue from beneficiaries willing to pay for premium materials. This shifts cost from Medicare to beneficiaries, potentially increasing out-of-pocket spending for wheelchair users. The primary beneficiaries are DME suppliers who can now charge a premium for lightweight wheelchairs, and material suppliers (titanium, carbon fiber) who may see increased demand. However, the market size is small—ultralightweight manual wheelchairs are a niche within the broader DME market.
Structural winners include DME suppliers like Invacare (currently private) and smaller public companies with DME exposure. The bill's narrow scope means no major public company is directly and significantly impacted. PRVA (Privia Health) has a tangential connection through its physician network that coordinates DME, but the revenue impact is minimal. ENS (EnerSys) is a stretch—its lightweight battery systems for mobility devices could see indirect demand, but the link is weak.
The bill has a companion bill in the Senate (S247), increasing passage probability. It awaits floor action in the House. Given the unanimous committee vote and bipartisan sponsorship (Rep. Joyce, R-PA, with 9 cosponsors), passage is likely but timing is uncertain. No real market data was provided for stock prices, so no price trends are analyzed.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Requires CMS to establish separate HCPCS billing codes for ultralightweight manual wheelchair bases with titanium or carbon fiber construction, allowing suppliers to charge beneficiaries the difference between Medicare payment and actual charge.
Who must act
Suppliers of durable medical equipment (DME) under Medicare Part B, including those providing ultralightweight manual wheelchairs.
What happens
Suppliers can now bill beneficiaries for the incremental cost of premium materials (titanium/carbon fiber) above standard Medicare reimbursement, creating a new revenue stream for higher-margin wheelchair sales.
Stock impact
PRVA (Privia Health) operates a physician enablement platform that includes DME coordination; while not a direct DME supplier, its network of providers may see increased patient demand for premium wheelchairs, potentially driving modest incremental revenue from coordination fees.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.